Breaking News
4 hours ago
Simantini Singh Deo
Lungpacer Medical appoints Steven Pfanstiel as CFO, bringing nearly 25 years of medical device and biotech experience to advance AeroPace System commercialization and company growth.
Simantini Singh Deo
UroGen Pharma settles JELMYTO patent dispute with Teva, granting a non-exclusive generic license effective September 15, 2030, pending FDA approval and preserving core patent rights.
Simantini Singh Deo
J&J's nipocalimab met Phase 2 primary endpoint in SLE; Phase 3 underway, raising CMC and BLA readiness questions for FcRn blocker manufacturing.
Simantini Singh Deo

Novo Nordisk launches oral semaglutide in the UAE, the first market outside the US, with further launches confirmed for H2 2026.
Simantini Singh Deo
